Abstract BACKGROUND: Renal cell cancer ( RCC ) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%. Clusterin is a cell survival gene that increases in human renal tubular epithelial cells after various states of injury and disease. Downregulation of clusterin, using antisense oligonucleotides ( ASO ) , has recently been shown to increase chemosensitivity in several prostate cancer models. The objectives in this study were to evaluate clusterin expression levels in human RCC and normal kidney tissue, and to test whether clusterin ASO could also enhance chemosensitivity in human RCC Caki -2 cells both in vitro and in vivo. METHODS: Immunohistochemical staining was used to characterize clusterin expression in 67 RCC and normal kidney tissues obtained from radical nephrectomy specimens. Northern blot analysis was used to assess changes in clusterin mRNA expression after ASO and paclitaxel treatment. The effects of combined clusterin ASO and paclitaxel treatment on Caki -2 cell growth was examined using an MTT assay. Athymic mice bearing Caki -2 tumors were treated with clusterin ASO alone, clusterin ASO plus paclitaxel, and mismatch control oligonucleotides plus paclitaxel, over a period of 28 days with measurement of tumor volumes once weekly over 8 weeks. RESULTS: Immunohistochemistry of normal and malignant kidney tissue sections of 67 patients demonstrated positive clusterin staining for almost all RCC ( 98% ) and an overexpression, compared to normal tissue, in a majority of RCC ( 69% ) . Clusterin ASO, but not mismatch control oligonucleotides, decreased clusterin mRNA expression in Caki -2 cells in a dosedependent and sequence -specific manner. Pretreatment of Caki -2 cells with clusterin ASO significantly enhanced chemosensitivity to paclitaxel in vitro. Characteristic apoptotic DNA laddering was observed after combined treatment with ASO plus paclitaxel, but not with either agent alone. In vivo administration of clusterin ASO plus paclitaxel acted synergistically to increase apoptosis and significantly delay Caki -2 tumor growth, compared to mismatch control oligonucleotide plus paclitaxel. In addition, TUNEL staining revealed increased apoptotic cells in tumors treated with clusterin ASO plus paclitaxel compared to treatment with either clusterin ASO or paclitaxel alone. CONCLUSION: These findings confirm that the use of clusterin ASO may be a feasible strategy to enhance chemosensitivity for patients with advanced RCC.
Introduction
Renal cell cancers ( RCCs ) account for approximately 2% of adult carcinomas with over 30,000 new cases per year in the United States and an associated 12,000 deaths [ 1 ] . Estimates of annual new diagnoses of RCC have been increasing steadily [ 1, 2 ] . Despite extensive evaluation of many different treatment modalities, advanced metastatic RCC remains highly resistant to systemic therapy. To date, no chemotherapy is established for the treatment of advanced kidney cancer with objective response rates higher than 15% that justifies its use as a single agent [ 3 ] . Combinations of chemotherapy plus hormonal agents have been studied but likewise are ineffective and result in additive toxicity. Nearly half of all patients with RCC die within 5 years of diagnosis and 5 -year survival for those with metastatic disease is 5% to 10% [ 4 ] . Therefore, to make a significant impact on survival, preclinical and clinical evaluation of new agents and treatment programs to identify improved antitumor activity are priorities in this refractory disease.
Advances in the field of nucleic acid chemistry offers one attractive strategy to design antisense oligonucleotide ( ASO ) -based therapeutic agents that specifically hybridize with complementary mRNA regions of a target gene and thereby inhibit gene expression by forming RNA / DNA duplexes [ 5 ] . Several ASO targeted against specific genes involved in neoplastic progression have been evaluated as potential therapeutic agents [6] [7] [8] [9] . Collectively, these findings identify ASO as a novel class of antineoplastic agents when designed for appropriate molecular targets.
However, because numerous genes are involved in tumor progression, inhibition of a single target gene will likely be insufficient to inhibit tumor progression in a meaningful way. In fact, combined use of ASO with other compounds, such as chemotherapeutic agents, have been demonstrated to produce more potent antineoplastic effects in several tumor models [ 10 -13 ] .
Clusterin, also known as testosterone -repressed prostate message -2 ( TRPM -2 ) or sulfated glycoprotein -2, was first described in 1983 as a major secretory glycoprotein produced by ram Sertoli cells [ 14 ] . It is associated with a wide variety of physiologic and pathologic processes, including tissue remodeling, lipid transport, membrane protection, complement defense, and apoptotic cell death [ 15 ] . Increased expression of clusterin is seen in a variety of renal diseases such as renal dysplasia, membranous glomerulonephritis, inherited polycystic renal diseases, and RCC [ 16, 17 ] . It is also induced following ureteric obstruction, ischemia / reperfusion injury, and in nephrotoxic injuries such as gentamicin nephrotoxicity and myoglobinuric failure [ 18 ] . More recent observations suggest that clusterin acts in a chaperone -like manner similar to that of small heat shock proteins. It potently inhibits stress -induced protein precipitation in vitro and appears to be associated with cell survival in vivo [ 19 ] . Inactivation of this gene could therefore impair cellular repair mechanisms in response to external cell death signals such as chemotherapy.
Paclitaxel is one of the most important anticancer drugs developed in the past two decades and has shown significant activity against a variety of adenocarcinomas [ 20 ] . Polymeric micellar paclitaxel used in this study offers a safe and convenient formulation for animal studies with no significant toxicity [ 21 ] . We recently reported that clusterin overexpression confers chemoresistance to paclitaxel in the human prostate LNCaP tumor model [ 22 ] . In the present study, we demonstrate for the first time that downregulation of a specific gene ( clusterin ) , using sequence -specific ASO, enhances the response of human RCC to paclitaxel chemotherapy both in vitro and in vivo.
Materials and Methods

Tumor Cell Line
Caki -2 is derived from a human clear cell carcinoma of the kidney. It was purchased from the American Type Culture Collection ( Rockville, MD ) . Cells were maintained in Mc Coy's 5a medium ( Life Technologies, Gaithersburg, MD ) supplemented with 10% heat -inactivated fetal calf serum.
Chemotherapeutic Agents
Paclitaxel was purchased from Sigma ( St. Louis, MO ) . Stock solutions of paclitaxel were prepared with dimethyl sulfoxide ( DMSO ) , and diluted with PBS to the required concentrations before each in vitro experiment. Polymeric micellar paclitaxel used in these in vivo studies was generously supplied by Dr. Helen M. Burt ( Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada ) .
Antisense Clusterin Oligonucleotides ( Clusterin ASO )
Phosphorothioate oligonucleotides used in this study were purchased from La Jolla Pharmaceuticals ( La Jolla, CA ) . The sequence of clusterin ASO corresponding to the human clusterin translation initiation site was 5 0 -CAGCAG-
was used as control.
Treatment of Cells with Oligonucleotides
Lipofectin, a cationic lipid ( Life Technologies ) was used to increase oligonucleotide uptake of cells. Caki -2 cells were treated with various oligonucleotide concentrations after preincubation for 20 minutes with 20 g / ml lipofectin in serum free OPTI -MEM ( Life Technologies ) . Four hours after the beginning of the incubation, the medium containing oligonucleotides and lipofectin was replaced with standard culture medium described above.
Northern Blot Analysis
Total RNA was isolated from cultured Caki -2 cells and Caki -2 tumor tissues using the acid -guanidium thiocyanate -phenol -chloroform method. Electrophoresis, hybridization, and washing conditions were carried out as previously reported [ 9 ] . Human clusterin and GAPDH cDNA probes were generated by reverse transcription -PCR from total RNA of human kidney using primers 
MTT Assay
The in vitro growth inhibitory effects of clusterin ASO plus paclitaxel on Caki -2 cells were assessed using the MTT assay as described previously [ 23 ] . Briefly, 1Â10 4 cells were seeded in each well of 96 -well microtiter plates and allowed to attach overnight. Cells were then treated once daily with 500 nM ASO for 2 days. Following ASO treatment, cells were treated with various concentrations of paclitaxel. After 48 hours of incubation, 20 l of 5 mg / ml MTT ( Sigma ) in PBS was added to each well, followed by incubation for 4 hours at 378C. The formazan crystals were dissolved in DMSO. The optical density was determined with a microculture plate reader ( Becton Dickinson Labware, Lincoln Park, NJ ) at 540 nm. Absorbance values were normalized to the values obtained for the vehicletreated cells to determine the percentage of survival. Each assay was performed in triplicate.
DNA Fragmentation Analysis
The nucleosomal DNA degradation was analyzed as described previously with a minor modification [ 23 ] . Briefly,
1Â10
5 Caki -2 cells were seeded in 10 -cm culture dishes and allowed to adhere overnight. After treatment with ASO plus paclitaxel using the same schedule as described above, cells were harvested and then lysed in a solution containing 100 mM NaCl, 10 mM Tris pH 7.4, 25 mM EDTA and 0.5% SDS. After centrifugation, supernatants were incubated with 300 g / ml proteinase K for 5 hours at 658C and extracted with phenol -chloroform. The aqueous layer was treated with 0.1 volume of 3 M sodium acetate, and the DNA was precipitated with 2.5 volumes of 95% ethanol. Following treatment with 100 g / ml RNAse A for 1 hour at 378C, the sample was electrophoresed on a 2% agarose gel and stained with ethidium bromide.
Immunohistochemical Staining
Sections from formaldehyde -fixed, paraffin -embedded tissue from radical nephrectomy specimens for RCC were deparaffinized by passing slides through 5 -minute washes of xylene ( 2Â ) , 100% EtOH, 95% EtOH, and 70% EtOH, successively. Endogenous peroxidase was blocked with 3% hydrogen peroxide in absolute methanol. Slides were autoclaved for 15 minutes in DAKO target retrieval solution ( Dako, Carpinteria, CA ) , and blocked with 1% bovine serum albumin for 1 hour at room temperature. After an overnight incubation at 48C with 1:50 antihuman clusterin goat polyclonal IgG ( Santa Cruz Biotechnology, Santa Cruz, CA ) , sections were covered with 1:200 HRP -conjugated antigoat IgG ( Santa Cruz Biotechnology ) . Peroxidase activity on sections was detected by immersion in freshly mixed 3 -3 0 diaminobenzidine tetrachloride ( 0.6 mg / ml ) ( Sigma ) and 0.003% hydrogen peroxide for 5 minutes. The sections were then counterstained with hematoxylin, dehydrated and cleared, and placed under a coverslip. Each specimen was read independently by a pathologist ( M. A. ) and a urologist ( T. Z. ) . Clusterin -staining intensity was scored from 0 ( no staining at all ) , + 1 ( weak ) , + 2 ( medium ) , + 3 ( strong ) to + 4 ( very strong staining ) and the percentage of stained tissue per section was assessed. For each patient ( n = 67 ) , normal kidney tissue was compared with corresponding RCC tissue.
Assessment of In Vivo Tumor Growth
Approximately 1Â10 6 of Caki -2 cells were inoculated subcutaneously with 0.1 ml of Matrigel ( Becton Dickinson Labware, Bedford, MA ) in the flank region of 6 -to 8 -weekold male athymic mice ( BALB / c strain; Harlan SpragueDawley, Indianapolis, IN ) under halothane anesthesia ( 5% induction and 1.5% maintenance concentration ) . When Caki -2 tumors grew to 1 cm in diameter, usually 8 to 10 weeks after injection, mice were randomly selected for treatment with clusterin ASO alone, clusterin ASO plus paclitaxel, or mismatch control oligonucleotides plus paclitaxel. Each experimental group consisted of eight mice. After randomization, 12.5 mg / kg clusterin ASO or mismatch control oligonucleotide was injected intraperitoneally once daily into each mouse for 28 days. From day 10 to 14, and from day 24 to 28, 0.5 mg polymeric micellar paclitaxel was administered once daily by intravenous injection. Tumor volume was measured once weekly and calculated by the formula lengthÂwidthÂdepthÂ0.5236 [ 24 ] . Data points were reported as mean tumor volumes ± standard deviation. All animal procedures were performed according to the guidelines of the Canadian Council on Animal Care and with appropriate institutional certification.
TUNEL Staining
A modified TUNEL technique [ 25 ] was used to detect apoptotic cells in Caki -2 tumors using the ApopTag in situ apoptosis detection system ( Oncor, Gaithersburg, MD ) . Briefly, sections from formaldehyde -fixed, paraffin -embedded Caki -2 tumors were deparaffinized and endogenous peroxidase was blocked as described above for immunohis- tochemical staining. After pretreatment with proteinase K ( 10 g / ml ) , slides were labeled with biotinylated poly dU, introduced by terminal deoxy -transferase, and then stained using antidigoxigenin -peroxidase according to manufacture's protocol. Peroxidase activity on sections was detected by immersion in freshly mixed 3 -3 0 diaminobenzidine tetrachloride ( 0.6 mg / ml ) ( Sigma ) and 0.003% hydrogen peroxide for 5 minutes. The sections were then counterstained with hematoxylin, dehydrated and cleared, and placed under a coverslip. The number of positively stained cells / high power field ( hpf ) in five random fields was counted and averaged.
Statistical Analysis
The in vitro cytotoxic effects of antisense or mismatch oligonucleotide and paclitaxel were analyzed with the use of a repeated -measure analysis of variance ( ANOVA ) model. Synergy between clusterin ASO and paclitaxel was analyzed by calculation of the fractional product parameter according to the fractional product method as previously described [ 26 ] . The other data were analyzed by Student's t test. The levels of statistical significance were set at P < .05 ( twosided ) , and all statistical calculations were done by use of the Statview 5.0 software ( Abacus Concepts, Berkeley, CA ) .
Results
Enhanced Expression of Clusterin in Human RCC
Clusterin immunostaining was performed in normal kidney and RCC tissue of 67 patients. Histologic classification of RCC revealed clear cell patterns in 56 cases ( 84.5% ) , the rest of sections showing either granular cell ( 6% ) or papillary cell patterns ( 9% ) . Staining of cytoplasmic clusterin was heterogenous both in normal and malignant tissues. Positive clusterin staining was found in almost all RCC ( 97% ) and clusterin overexpression, compared to normal tissue, was observed in a majority ( 69% ) of RCC. Fifty -three percent of normal kidney tissue samples ( distant from RCC ) showed no or only weak staining for clusterin, compared to only 15% of RCC ( Figure 1, Table 1 ) . hours, mRNA was then extracted and analyzed for clusterin levels by Northern blotting. Clusterin mRNA levels increased in a dose -dependent manner by paclitaxel treatment at concentrations up to 100 nM. Quantitative analysis of clusterin mRNA levels ( after normalization to GAPDH mRNA levels ) was performed by laser densitometry. Each column represents the mean value of triplicate analysis with standard deviation. Numbers on the Y axis symbolize arbitrary densitometric units.
Sequence -Specific and Dose -Dependent Inhibition of Clusterin Expression by Clusterin ASO in Caki -2 Cells
Northern blot analysis was used to determine the effect of treatment with clusterin ASO on clusterin mRNA expression in Caki -2 cells. As shown in Figure 2 , daily treatment of Caki -2 cells with clusterin ASO ( 50, 100, 500, or 1000 nM ) for 2 days reduced clusterin mRNA levels by 42%, 58%, 61%, and 64%, respectively, whereas clusterin mRNA expression was not affected by mismatch control oligonucleotides at any of the employed concentrations.
Effects of Paclitaxel Treatment on Clusterin mRNA Expression in Caki -2 Cells and Tumors
Northern blot analysis was used to determine the effects of paclitaxel treatment on clusterin mRNA expression in Caki -2 cells in vitro and tumors in vivo, respectively. As shown in Figure 3 , clusterin mRNA induction increased in a dose -dependent manner after paclitaxel treatment in vitro up to 73% at concentrations of 100 nM.
To determine whether paclitaxel changes clusterin mRNA expression in Caki -2 tumors in vivo, 0.5 mg polymeric micellar paclitaxel was administered intravenously once daily over 10 days with harvest of tumors for mRNA extraction 1 day later. In nude mice bearing Caki -2 tumors, clusterin mRNA levels increased by 15% after treatment with paclitaxel compared to untreated control ( Figure 4 ) .
Downregulation of Clusterin Expression by Clusterin ASO in Caki -2 Tumors
To determine whether ASO treatment inhibits clusterin expression in Caki -2 tumors in vivo, tumor -bearing nude mice were given 12.5 mg / kg clusterin ASO or mismatch control oligonucleotides intraperitoneally once daily over 28 days with tumors harvested for mRNA extraction 1 day later. Treatment with clusterin ASO resulted in a 51% reduction in clusterin mRNA levels in Caki -2 tumors Figure 4 . Effects of single and combined treatment with either clusterin ASO, mismatch control oligonucleotide or micellar paclitaxel on clusterin expression of Caki -2 tumors in vivo. For that purpose, six athymic mice bearing Caki -2 tumors were randomly selected as control ( no treatment ) ( Lane 1 ) , treatment with either clusterin ASO ( Lane 2 ) , mismatch control oligonucleotide ( Lane 3 ) , or micellar paclitaxel alone ( Lane 4 ) , clusterin ASO plus micellar paclitaxel ( Lane 5 ) or mismatch control oligonucleotides plus micellar paclitaxel ( Lane 6 ) . After randomization, 12.5 mg / kg clusterin ASO or mismatch control oligonucleotides were injected intraperitoneally once daily for 28 days. From day 10 to 14, and from day 24 to 28, 0.5 mg polymeric micellar paclitaxel was administered once daily by intravenous injection. Tumors of all mice were harvested on day 29 for mRNA extraction. Compared to control, clusterin ASO treatment decreased clusterin mRNA levels by 51%, whereas paclitaxel increased clusterin mRNA levels by 15%. Combined treatment with clusterin ASO and paclitaxel decreased clusterin mRNA levels by 28%. Quantitative analysis of clusterin mRNA levels ( after normalization to GAPDH mRNA levels ) was performed by laser densitometry. Each column represents the mean value of triplicate analysis with standard deviation. Figure 5 . Effect of combined treatment with clusterin ASO and paclitaxel on Caki -2 cell growth and apoptosis. ( A ) Caki -2 cells were treated daily with either 500 nM clusterin ASO or mismatch control oligonucleotides once daily for 2 days. Following oligonucleotide treatment, the medium was replaced with medium containing various concentrations of paclitaxel. After 48 hours of incubation, cell viability was determined by the MTT assay. Each data point represents the mean of triplicate analysis with standard deviation. Clusterin ASO treatment significantly enhanced chemosensitivity of paclitaxel in a dose -dependent manner ( two -sided, P = .022, ANOVA ) , reducing the IC 50 ( i.e., the concentration that reduces cell viability by 50% ) of paclitaxel by 80% ( 320 nM to 65 nM ) , whereas mismatch control oligonucleotides had no effect. The combined effects between clusterin ASO and paclitaxel were synergistic ( P < .05 ) , as determined by an analysis that utilized the fractional product method [ 26 ] . ( B ) DNA fragmentation assay was performed to compare induction of apoptosis after combined treatment with 500 nM clusterin ASO and paclitaxel ( 7.5 nM ) . After the same treatment schedule described above, characteristic DNA laddering was observed only after combined treatment with clusterin ASO and paclitaxel.
compared to mismatch control oligonucleotide -treated tumors ( Figure 4 ) .
Enhanced Chemosensitivity of Caki -2 Cells In Vitro After Clusterin ASO Treatment
To determine whether treatment with clusterin ASO enhances the cytotoxic effects of paclitaxel, Caki -2 cells were treated with 500 nM clusterin ASO or mismatch control oligonucleotides once daily for 2 days and then incubated with medium containing various concentrations of paclitaxel for 2 days. The MTT assay was then performed to determine cell viability. As shown in Figure 5A , clusterin ASO treatment significantly enhanced chemosensitivity of paclitaxel in a dose -dependent manner ( two -sided, P = .022, ANOVA ) , reducing the IC 50 ( i.e., the concentration that reduces cell viability by 50% ) of paclitaxel by 80% ( 320 nM to 65 nM ) , whereas mismatch control oligonucleotides had no effect. The combined effects between clusterin ASO and paclitaxel were synergistic ( P < .05 ) , as determined by an analysis that utilized the fractional product method [ 26 ] .
DNA fragmentation assay was performed to compare induction of apoptosis after combined treatment with 500 nM clusterin ASO and 10 nM paclitaxel. After the same treatment schedule described above, characteristic apoptotic DNA laddering was observed only after combined treatment with clusterin ASO and paclitaxel ( Figure 5B ) . 
Enhanced Chemosensitivity of Caki -2 Tumors In Vivo After Clusterin ASO Treatment
Male athymic mice bearing Caki -2 tumors approximately 1 cm in diameter were randomly selected for treatment with clusterin ASO plus paclitaxel, mismatch control oligonucleotides plus paclitaxel, or clusterin ASO alone. Mean tumor volume was similar at the beginning of treatment in each of these groups ( 365 to 375 mm 3 ) . After randomization, 12.5 mg / kg clusterin ASO or mismatch control oligonucleotides were injected intraperitoneally once daily for 28 days. From day 10 to 14, and from day 24 to 28, 0.5 mg polymeric micellar paclitaxel was administered once daily by intravenous injection. As shown in Figure 6A , clusterin ASO enhanced micellar paclitaxel chemosensitivity in Caki -2 tumors, causing a 50% reduction in mean tumor volume 7 weeks after initiation of treatment, compared to treatment with mismatch control oligonucleotides and paclitaxel ( twosided, P < .05 ) . In vivo, the combined effects between clusterin ASO and paclitaxel were also synergistic ( P < .05 ) , as analyzed by the fractional product method [ 26 ] . In addition, TUNEL staining detected a three -fold increase in the numbers of apoptotic cells in Caki -2 tumors treated with clusterin ASO plus micellar paclitaxel ( mean number of apoptotic cells / high power field: 11.6 ) , compared to those treated with mismatch control oligonucleotides plus micellar paclitaxel ( mean number of apoptotic cells / high power field: 4.1 ) , or clusterin ASO alone ( mean number of apoptotic cells / high power field: 2.3 ) ( Figure 6B À D ) . Under the experimental conditions used in the above in vivo experiments, no side effects associated with ASO treatment and / or chemotherapy were observed ( except one animal developing ascites, 3 weeks after clusterin ASO treatment was finished ) .
Discussion
Numerous systemic therapies have been studied to assess their activity in advanced, metastatic RCC. From 1990 through October 1998, 33 chemotherapeutic agents were studied in 51 phase II trials comprising 1347 patients [ 4 ] . No chemotherapeutic agent produced response rates that would justify its use as a single -agent therapy. Hormonal therapy with medroxyprogesterone produces infrequent responses ( < 10% ) and had no effect on survival [ 27 ] . Only a few patients exhibit complete or partial responses to immunologic agents like interferon and / or interleukin -2 but most do not respond, and there are few long -term survivors [ 1, 28, 29 ] . Despite extensive evaluation of many different treatment modalities, advanced RCC remains highly resistant to systemic therapy. Therefore, novel therapeutic strategies targeting molecular mechanisms mediating chemoresistance are required.
Recent preclinical studies have provided proof of principle evidence that targeting antiapoptotic genes using ASO enhances apoptosis induced by conventional cytotoxic chemotherapy [ 10 -12 ] . Clusterin is one of many antiapoptotic genes involved in cancer progression and the development of chemoresistance. Acting in a chaperone -like manner similar to small heat shock proteins, it helps prevent apoptosis induced by external stimuli such as chemotherapeutic agents [ 19 ] . We recently demonstrated for several prostate cancer models that the efficacy of chemotherapeutic agents can be improved by combination with clusterin ASO [ 21, 30 ] . In the kidney, increased expression of clusterin is observed in a number of acute and chronic states of renal injury and disease. However, little is known about changes of clusterin expression levels in kidney cancer. Based on the analysis of only four patients, Parczyk et al. [ 17 ] reported a three -fold overexpression of clusterin in human RCC compared to normal kidney tissue. In our study, we compared normal and malignant kidney tissues of 67 patients using clusterin immunostaining. Positive clusterin staining ( + 1 to + 4 ) was observed in almost all RCC ( 97% ) and increased clusterin expression compared to normal tissue in a majority of RCC ( 69% ) . Fifty -three percent of normal kidney tissue samples distant from RCC showed no or only weak staining for clusterin ( 0 to + 1 ) consistent with findings of other investigators [ 17, 31 ] . To clarify the functional role of increased clusterin expression in RCC, we then tested the effects of clusterin ASO on human Caki -2 RCC cell growth and whether clusterin ASO could enhance the cytotoxic effects of paclitaxel in this model system.
Phosphorothioate clusterin ASO used in this study significantly inhibited expression of clusterin mRNA in Caki -2 cells both in vitro and in vivo. Sequence specificity was confirmed using a two -base clusterin mismatch oligonucleotide, which had no effects on clusterin expression in Caki -2 cells. When used alone, antisense or mismatch oligonucleotide treatment had no effect on Caki -2 cell growth. However, when administered in combination with other cell death stimuli, like cytotoxic chemotherapy, clusterin ASO enhanced Caki -2 cell apoptosis both in vitro and in vivo. Pretreatment of Caki -2 cells with clusterin ASO reduced the IC 50 of paclitaxel by 80%, thereby enhancing apoptosis induced by these agents. Consistent with these in vitro results, synergistic effects of combined use of clusterin ASO plus paclitaxel was also observed in vivo. Systemic administration of clusterin ASO plus polymeric micellar paclitaxel suppressed the Caki -2 tumor growth by 50%, compared to treatment with mismatch control oligonucleotides plus paclitaxel. Detection of increased apoptotic cells after combined ASO and chemotherapy by TUNEL staining in Caki -2 tumors suggest that decrease in tumor progression rates after combined clusterin ASO plus paclitaxel resulted from enhanced chemotherapy -induced apoptosis rather than decreased cell proliferation.
The results in the present study suggest that increased clusterin helps mediate RCC progression by inhibiting apoptotic cell death induced by several kinds of therapies, including cytotoxic chemotherapy. Decreasing clusterinmediated chemoresistance by clusterin ASO may provide a feasible and safe strategy to enhance chemosensitivity in advanced RCC. The preclinical data presented here provide proof of principle support for designing clinical studies employing combined clusterin ASO plus paclitaxel therapy for patients with advanced RCC.
